Stock Events

Stock Events

Tyra Biosciences 

$33.18
0
+$0+0% Friday 08:03

Statistics

Day High
33.18
Day Low
33.09
52W High
-
52W Low
-
Volume
1,956
Avg. Volume
-
Mkt Cap
1.77B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-0.58
-0.56
-0.53
-0.5
Expected EPS
-0.584667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-172.96MNet Income

Analyst Ratings

$51.00Average Price Target
The highest estimate is 59.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TYRA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with Tyra Biosciences' focus on precision medicine for cancer and other diseases.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing space, directly competing with Tyra Biosciences in developing treatments for genetically defined diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading developer of CRISPR gene editing therapies, potentially competing with Tyra Biosciences in the area of genetic disease treatment.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics focuses on precision genetic medicines using base editing, a form of gene editing that could rival Tyra Biosciences' therapeutic approaches.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, which competes with Tyra Biosciences' precision medicine efforts.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is pioneering allogeneic CAR T cell therapies, a new approach to cancer treatment that could compete with Tyra Biosciences' oncology focus.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer and immune disorders, competing with Tyra Biosciences in the immuno-oncology space.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for cancer and genetic diseases, competing with Tyra Biosciences on multiple fronts.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, with its strong focus on antiviral drugs and cancer therapies, competes with Tyra Biosciences in the development of innovative treatments for serious illnesses.

About

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Show more...
CEO
ISIN
US90240B1061

Listings

BOATS
BOATS
TYRA.BOATS
XNAS
US
TYRA

0 Comments

Share your thoughts

FAQ

What is Tyra Biosciences stock price today?▼
The current price of TYRA.BOATS is $33.18 USD — it has increased by +0% in the past 24 hours. Watch Tyra Biosciences stock price performance more closely on the chart.
What is Tyra Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tyra Biosciences stocks are traded under the ticker TYRA.BOATS.
What is Tyra Biosciences market cap?▼
Today Tyra Biosciences has the market capitalization of 1.77B
When is the next Tyra Biosciences earnings date?▼
Tyra Biosciences is going to release the next earnings report on April 30, 2026.
What were Tyra Biosciences earnings last quarter?▼
TYRA.BOATS earnings for the last quarter are -0.57 USD per share, whereas the estimation was -0.53 USD resulting in a -7.24% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tyra Biosciences revenue for the last year?▼
Tyra Biosciences revenue for the last year amounts to 0 USD.
What is Tyra Biosciences net income for the last year?▼
TYRA.BOATS net income for the last year is -172.96M USD.
When did Tyra Biosciences complete a stock split?▼
Tyra Biosciences has not had any recent stock splits.